Efficacy and safety of karelizumab combined with simultaneous radiotherapy and chemotherapy for esophageal cancer
Objective To investigate the therapeutic effect and safety of camrelizumab combined with simultane-ous radiotherapy and chemotherapy for esophageal cancer.Methods The clinical data of 156 patients with esopha-geal cancer treated in Yuncheng Central Hospital from September 2020 to September 2023 were retrospectively analyzed.The patients were divided into the combination group(karelizumab combined with simultaneous radiotherapy and che-motherapy,n=78)and the control group(simultaneous radiotherapy and chemotherapy,n=78)according to the treat-ment modality.The therapeutic effect,programmed death 1(PD-1)and programmed cell death 1 ligand 1(PD-L1)lev-els,quality of life evaluation and the toxicological reaction were compared between the two groups.Results After treatment,the objective remission and disease control rates in the combination group were 79.49%(62/78)and 96.15%(75/78),respectively,which were higher than those of 60.26%(47/78)and 82.05%(64/78)in the control(χ2=6.851,7.988,both P＜0.05).The PD-1 and PD-L1 levels in the combination group((201.81±16.12)ng·L-1 and(264.32±25.10)ng·L-1)were lower than those in the control group((232.23±19.58)ng·L-1 and(301.28±27.42)ng·L-1)(t=10.593,8.781,both P＜0.05).The rate of improvement in the quality of life in the combined group was 85.90%(67/78),which was higher than that of 71.79%(56/78)in the control,(χ2=4.650,P＜0.05).In terms of adverse reactions,the incidence of gastrointestinal re-actions,leukopenia,radiation esophagitis,anaemia and thrombocytopenia was increased in both groups,but they were mostly grade 1-2 adverse reactions,which could be tolerated by most of the patients.Meanwhile,it did not affect the course of treatment after symptomatic treatment.There was no significant difference in the probability of toxic side effects between the two groups(all P＞0.05).Conclusion Camrelizumab combined with simultaneous radiotherapy and chemotherapy has favourable thera-peutic results in patients with esophageal cancer since it can reduce serum PD-1 and PD-L1 levels,improve the quality of life of patients and does not increase the risk of adverse reactions as compared with conventional simultaneous radiotherapy.
Esophageal cancerCamrelizumabSimultaneous radiotherapy and chemotherapyEfficacySafety
万方数据
维普
